Insider Selling: Caribou Biosciences (NASDAQ:CRBU) Insider Sells $13,598.48 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Barbara Mcclung sold 6,938 shares of Caribou Biosciences stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $1.96, for a total transaction of $13,598.48. Following the completion of the sale, the insider owned 481,564 shares of the company’s stock, valued at $943,865.44. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Caribou Biosciences Stock Up 2.1%

CRBU opened at $1.99 on Friday. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.54. The business has a fifty day simple moving average of $1.63 and a 200-day simple moving average of $1.91. The firm has a market cap of $186.01 million, a P/E ratio of -1.17 and a beta of 2.61.

Hedge Funds Weigh In On Caribou Biosciences

Several large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in Caribou Biosciences by 80.0% during the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after buying an additional 10,824 shares during the last quarter. Green Alpha Advisors LLC boosted its holdings in Caribou Biosciences by 3.1% in the fourth quarter. Green Alpha Advisors LLC now owns 375,139 shares of the company’s stock valued at $596,000 after purchasing an additional 11,440 shares in the last quarter. CWM LLC increased its stake in Caribou Biosciences by 53.5% in the second quarter. CWM LLC now owns 33,839 shares of the company’s stock valued at $43,000 after purchasing an additional 11,798 shares during the last quarter. R Squared Ltd acquired a new stake in Caribou Biosciences during the third quarter worth approximately $29,000. Finally, Bronte Capital Management Pty Ltd. purchased a new stake in shares of Caribou Biosciences during the 4th quarter worth approximately $25,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on CRBU shares. Citigroup boosted their price target on shares of Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 3rd. Truist Financial set a $7.00 target price on shares of Caribou Biosciences in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Finally, HC Wainwright lifted their target price on Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.